ADRA2C Protein (Alpha-2C Adrenergic Receptor)

ADRA2C Protein (Alpha-2C Adrenergic Receptor)

<div class="infobox infobox-protein">
| Property | Value |
|----------|-------|
| Protein Name | Alpha-2C Adrenergic Receptor (ADRA2C) |
| Gene | ADRA2C |
| UniProt ID | P08913 |
| Molecular Weight | ~46 kDa (462 aa) |
| Subcellular Localization | Plasma membrane, G-protein coupled receptor |
| Protein Family | G-protein coupled receptor, adrenergic receptor family |
| Agonists | Clonidine, guanfacine, dexmedetomidine |
| Antagonists | Yohimbine, idazoxan |

</div>

Overview

The Alpha-2C adrenergic receptor (ADRA2C) is a G-protein coupled receptor (GPCR) that plays crucial roles in regulating sympathetic nervous system function, neurotransmitter release, and cellular responses to catecholamines. As one of the nine known adrenergic receptor subtypes (α1A, α1B, α1D, α2A, α2B, α2C, β1, β2, β3), ADRA2C is distinguished by its unique pharmacological profile, tissue distribution, and physiological functions. The receptor is widely expressed in the central and peripheral nervous systems, as well as in various peripheral tissues, where it modulates neurotransmission, hormone release, and cellular homeostasis.

ADRA2C Protein (Alpha-2C Adrenergic Receptor)

<div class="infobox infobox-protein">
| Property | Value |
|----------|-------|
| Protein Name | Alpha-2C Adrenergic Receptor (ADRA2C) |
| Gene | ADRA2C |
| UniProt ID | P08913 |
| Molecular Weight | ~46 kDa (462 aa) |
| Subcellular Localization | Plasma membrane, G-protein coupled receptor |
| Protein Family | G-protein coupled receptor, adrenergic receptor family |
| Agonists | Clonidine, guanfacine, dexmedetomidine |
| Antagonists | Yohimbine, idazoxan |

</div>

Overview

The Alpha-2C adrenergic receptor (ADRA2C) is a G-protein coupled receptor (GPCR) that plays crucial roles in regulating sympathetic nervous system function, neurotransmitter release, and cellular responses to catecholamines. As one of the nine known adrenergic receptor subtypes (α1A, α1B, α1D, α2A, α2B, α2C, β1, β2, β3), ADRA2C is distinguished by its unique pharmacological profile, tissue distribution, and physiological functions. The receptor is widely expressed in the central and peripheral nervous systems, as well as in various peripheral tissues, where it modulates neurotransmission, hormone release, and cellular homeostasis.

ADRA2C belongs to the α2-adrenergic receptor subfamily, which also includes the α2A (ADRA2A) and α2B (ADRA2B) subtypes. These receptors share the common feature of coupling to Gi/o proteins, leading to inhibition of adenylate cyclase and reduction of intracellular cAMP levels. However, each subtype exhibits distinct expression patterns and functional characteristics. ADRA2C is notably expressed in brain regions involved in cognition, mood, and motor control, as well as in peripheral tissues including platelets, adipocytes, and vascular smooth muscle.

Protein Structure and Pharmacology

Structural Features

ADRA2C is a prototypical Class A GPCR with seven transmembrane domains:

• N-terminal extracellular domain: Short, glycosylated sequence involved in receptor folding and ligand binding
• Seven transmembrane helices (TM1-TM7): Form the ligand-binding pocket and G-protein interface
• Three extracellular loops (ECL1-ECL3): Contain key residues for ligand recognition
• Three intracellular loops (ICL1-ICL3): Coupling domain for G-protein interaction
• C-terminal cytoplasmic domain: Involved in receptor desensitization and trafficking

Pharmacological Profile

ADRA2C exhibits unique pharmacological characteristics:

Agonists

• Clonidine: Mixed α2-adrenergic agonist, used as antihypertensive and analgesic
• Guanfacine: Selective α2A agonist, approved for ADHD treatment
• Dexmedetomidine: Highly selective α2 agonist, used in sedation
• Medetomidine: Veterinary sedative with α2 agonist activity

Antagonists

• Yohimbine: α2-selective antagonist, used in research and erectile dysfunction
• Idazoxan: Non-selective α2 antagonist
• Atipamezole: Selective α2 antagonist, medetomidine reversal

Subtype Selectivity

ADRA2C shows intermediate selectivity among α2 subtypes:

• Lower affinity for clonidine than α2A
• Higher affinity for certain antagonists compared to α2A
• Distinct binding pocket compared to other subtypes

Normal Cellular Function

G-Protein Coupling and Signaling

ADRA2C primarily couples to Gi/o family G-proteins:

Neurotransmitter Regulation

In the central nervous system, ADRA2C modulates neurotransmitter release:

• Norepinephrine: Autoreceptor function reduces NE release
• Dopamine: Modulates dopaminergic neurotransmission
• Serotonin: Influences serotonin release and mood
• Glutamate: Indirect effects on excitatory neurotransmission

Peripheral Functions

• Platelets: α2C receptors mediate aggregation responses
• Adipose Tissue: Regulate lipolysis and thermogenesis
• Vascular Smooth Muscle: Contribute to vasoconstriction regulation
• Pancreas: Modulate insulin secretion

Role in Neurodegeneration

Alzheimer's Disease

ADRA2C signaling impacts multiple aspects of AD pathogenesis:

Neuroinflammation Modulation

• ADRA2C activation inhibits microglial activation
• Reduced pro-inflammatory cytokine production
• Modulation of neurotoxic glial responses
• Potential for therapeutic intervention

Cognitive Function

• α2-adrenergic signaling affects attention and memory
• ADRA2C polymorphisms associated with cognitive performance
• Agonists may improve working memory in some populations
• Complex role in hippocampal synaptic plasticity

Amyloid and Tau Pathology

• α2-adrenergic agonists may reduce amyloid burden
• Effects on tau phosphorylation under investigation
• Modulation of APP processing

Parkinson's Disease

ADRA2C plays several roles in PD pathophysiology:

Motor Function

• Regulation of dopaminergic tone
• Modulation of motor cortex excitability
• Influence on levodopa-induced dyskinesias

Non-Motor Symptoms

• Sleep dysfunction: α2-adrenergic involvement in REM behavior disorder
• Mood disorders: Depression and anxiety in PD
• Autonomic dysfunction: Blood pressure regulation

Neuroprotection

• Potential neuroprotective effects of α2 agonists
• Modulation of oxidative stress
• Effects on mitochondrial function

Amyotrophic Lateral Sclerosis

• ADRA2C expression changes in motor neurons
• Modulation of glutamate release
• Potential involvement in excitotoxicity

Multiple System Atrophy

• Dysregulation of autonomic function
• Cardiovascular regulation abnormalities

Therapeutic Applications

Current Clinical Uses

| Drug | Indication | Mechanism |
|------|-------------|-----------|
| Clonidine | Hypertension, pain | α2-adrenergic agonist |
| Guanfacine | ADHD | α2A-selective agonist |
| Dexmedetomidine | ICU sedation | Selective α2 agonist |
| Brimonidine | Glaucoma | α2-adrenergic agonist |

Potential Neurodegeneration Therapies

Cognitive Enhancement

• α2-agonists for attention and memory
• Guanfacine for frontostriatal dysfunction
• Combination with cholinergic approaches

Neuroprotection

• Anti-inflammatory effects
• Modulation of excitotoxicity
• Antioxidant properties

Symptom Management

• Motor symptoms in PD
• Sleep disorders
• Autonomic dysfunction

Drug Development Strategies

• Subtype-Selective Agonists: Targeting specific α2 subtypes
• Peripherally-Acting Compounds: Reducing central side effects
• Allosteric Modulators: Novel binding sites
• biased Signaling: G-protein vs β-arrestin pathways

Genetic Studies

Polymorphisms

• Promoter variants: Affect receptor expression levels
• Coding variants: Alter ligand binding and signaling
• Linkage disequilibrium: Haplotype structures in populations

Disease Associations

• ADHD: ADRA2C variants modify risk and treatment response
• Schizophrenia: Associations with cognition
• Depression: Treatment response predictors
• Neurodegenerative diseases: Ongoing investigation

Animal Models

| Model | Application | Findings |
|-------|-------------|----------|
| Knockout mice | Gene function | Altered behavior, metabolism |
| Transgenic | Overexpression | Gain-of-function phenotypes |
| Conditional KO | Cell-type specific | Tissue-specific roles |

Research Directions

Current Questions

• What determines cell-type specific functions of ADRA2C?
• Can subtype-selective drugs achieve better therapeutic outcomes?
• What is the role of β-arrestin signaling vs G-protein signaling?
• How do ADRA2C polymorphisms affect disease risk and treatment?

Emerging Areas

• biased Ligands: Exploit pathway-selective signaling
• Structural Biology: Cryo-EM structures of α2 receptors
• Single-Cell Studies: Cell-type specific expression patterns
• Gene Therapy: Viral vector-mediated expression modulation

See Also

• [ADRA2C Gene](/genes/adra2c)
• [Adrenergic Signaling Pathway](/mechanisms/adrenergic-signaling)
• [G-Protein Coupled Receptors](/mechanisms/gpcr-signaling)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathway)

External Links

• [UniProt P08913 - ADRA2C](https://www.uniprot.org/uniprot/P08913)
• [NCBI Gene: ADRA2C](https://www.ncbi.nlm.nih.gov/gene/152)
• [IUPHAR/BPS Guide to Pharmacology](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=17)
• [Human Protein Atlas: ADRA2C](https://www.proteinatlas.org/ENSG00000144152-ADRA2C)

References